FDA Clears Dexcom Stelo OTC for Ages 2+ Based on Type 1 Diabetes Trial Data
FDA expanded Stelo to OTC pediatric use on extrapolated G7 type 1 data. Evidence gaps remain for non-diabetic toddlers regarding behavioral harms and clinical benefit. RCTs in at-risk preschoolers are needed before routine adoption.
The clearance rests on a premarket notification citing a single study of the prescription Dexcom G7 in children and adolescents with type 1 diabetes. That interventional trial measured time in range and hypoglycemia frequency but did not evaluate Stelo in healthy or prediabetic children. No RCT data exist for long-term metabolic or behavioral outcomes when sensors are applied to 2-year-olds without insulin-requiring disease.
Rising youth prediabetes prevalence (approximately 1 in 3 adolescents) creates pressure for earlier monitoring tools, yet observational cohorts show CGM use outside insulin therapy correlates with increased parental anxiety and restrictive feeding without proven reduction in progression to type 2 diabetes. Pediatric endocrinologists note insurance barriers persist for at-risk groups, while over-the-counter availability may primarily reach families already engaged in wellness tracking.
AAP has issued no position. Next required evidence includes a prospective RCT in children aged 2-6 at elevated diabetes risk, tracking both glycemic metrics and disordered-eating incidence over at least 12 months.
Dexcom: OTC Stelo sales to US households with children under 6 will exceed 40,000 units within 12 months of clearance.
Sources (2)
- [1]FDA 510(k) Summary for Dexcom Stelo(https://www.fda.gov/medical-devices)
- [2]G7 Accuracy and Outcomes in Youth with Type 1 Diabetes(https://diabetesjournals.org/care/article/46/4/789)